From Seekingalpha · · 50s
Thrivent Small Cap Fund Q3 2026 Performance
Thrivent Small Cap Fund matches Russell 2000 growth with AI-driven DNA demand.
In brief
Thrivent Small Cap Fund matches Russell 2000 growth with AI-driven DNA demand. Thrivent Small Cap Fund grew in line with Russell 2000 in Q3 2026 as AI drug development and cloud migrations boosted revenue. Originally reported by Seekingalpha.
Q3 2026 Performance

Thrivent Small Cap Fund performed roughly in-line with Russell 2000 Index over last quarter.
AI Drug Development Growth
Easing academic funding headwinds and growing demand for large-scale DNA inputs in AI-driven drug development support stronger revenue expectations.
Cloud Migrations Boost
We expect continued double-digit revenue growth supported near-term by cloud migrations and over time by demand to secure non-human identities.
Portfolio Adjustments
The investment thesis around improving nuclear power orders, new JV services wins, and accelerating shipbuilding growth has largely played out.
The big picture
Thrivent Small Cap Fund grew in line with Russell 2000 in Q3 2026 as AI drug development and cloud migrations boosted revenue.
Read the TL;DR — this story on one card.

